In either case, the findings in this study implicate innate immunity in MS pathogenesis from its onset and may provide novel insights into the fundamental disease process, along with new therapeutic targets and hope for personalized use of IFNβ. This evidence concerns the gene IFNB1 and myeloid sarcoma.